Inclusion Criteria:

- Patients must have histologically or cytologically confirmed colorectal carcinoma

- There are no restrictions on the amount or types of prior therapy

- Eligible patients must be receiving ongoing chemotherapy with an oxaliplatin
containing-regimen which is planned to continue for at least one month following
enrollment in this trial

- Any dose or schedule of oxaliplatin administration is allowed as long as patients
have self-reported taste disturbance that has either:

- 1) developed since the initiation of oxaliplatin-based therapy, or

- 2) a pre-existing, treatment-induced taste disturbance has subjectively worsened
since initiating oxaliplatin-based therapy

- Patients must have normal baseline self-reported taste perception prior to the
development of colorectal carcinoma

- Life expectancy of >= 3 months

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients with a subjective history of an extreme dry mouth syndrome that prevents
them from producing adequate amounts of saliva (approximately 2 mL in 15-20 min)

- Patients known to be human immunodeficiency virus (HIV)-positive

- Patients with any of the following conditions: untreated gastrointestinal reflux
disease; untreated diabetes mellitus; active thrush; active oral infection; active
mucositis

- Patients who are pregnant or breastfeeding are excluded